Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperpolarized Xenon MRI in IPF and cHP
NCT04677426Phase 2Withdrawn
- Sponsor
- University of Kansas Medical Center
- Start
- May 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of hyperpolarized xenon gas in idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis (HP), sponsored by University of Kansas Medical Center. Planned start May 2022; status: withdrawn.
02
Drugs
hyperpolarized xenon gas
03
Conditions
idiopathic pulmonary fibrosis (IPF)hypersensitivity pneumonitis (HP)
Beyond the preview
Go deeper on NCT04677426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04677426.